[1] |
Busse PJ, Christiansen SC. Hereditary angioedema[J]. N Engl J Med, 2020,382(12):1136⁃1148. doi: 10.1056/NEJMra1808012.
|
[2] |
Wang X, Lei S, Xu Y, et al. Mutation update of SERPING1 related to hereditary angioedema in the Chinese population[J]. Hereditas, 2022,159(1):28. doi: 10.1186/s41065⁃022⁃00242⁃z.
|
[3] |
Settipane RA, Bukstein DA, Riedl MA. Hereditary angioedema and shared decision making[J]. Allergy Asthma Proc, 2020,41(Suppl 1):S55⁃S60. doi: 10.2500/aap.2020.41.200057.
|
[4] |
Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema[J]. J Allergy Clin Immunol Pract, 2021,9(1):132⁃150. e3. doi: 10.1016/j.jaip.2020.08.046.
|
[5] |
Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema⁃the 2021 revision and update[J]. Allergy, 2022,77(7):1961⁃1990. doi: 10.1111/all.15214.
|
[6] |
Chyung Y, Vince B, Iarrobino R, et al. A phase 1 study investigating DX⁃2930 in healthy subjects[J]. Ann Allergy Asthma Immunol, 2014,113(4):460⁃466.e2. doi: 10.1016/j.anai. 2014.05.028.
|
[7] |
Syed YY. Lanadelumab: first global approval[J]. Drugs, 2018,78(15):1633⁃1637. doi: 10.1007/s40265⁃018⁃0987⁃2.
|
[8] |
FDA US. Drug trials Snapshots: TAKHZYRO[J/OL]. (2018⁃08⁃23). https://www.fda.gov/drugs/drug⁃approvals⁃and⁃databases/drug⁃trials⁃snapshots⁃takhzyro.
|
[9] |
Longhurst H, Farkas H. Biological therapy in hereditary angioedema: transformation of a rare disease[J]. Expert Opin Biol Ther, 2020,20(5):493⁃501. doi: 10.1080/14712598.2020. 1724280.
|
[10] |
Sterne J, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials[J]. BMJ, 2019,366:l4898. doi: 10.1136/bmj.l4898.
|
[11] |
Norris JM, Simpson BS, Ball R, et al. A modified Newcastle⁃Ottawa scale for assessment of study quality in genetic urological research[J]. Eur Urol, 2021,79(3):325⁃326. doi: 10.1016/j.eururo.2020.12.017.
|
[12] |
Banerji A, Busse P, Shennak M, et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis[J]. N Engl J Med, 2017,376(8):717⁃728. doi: 10.1056/NEJMoa1605767.
|
[13] |
Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial[J]. JAMA, 2018,320(20):2108⁃2121. doi: 10.1001/jama.2018.16773.
|
[14] |
Banerji A, Bernstein JA, Johnston DT, et al. Long⁃term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE Study[J]. Allergy, 2022,77(3):979⁃990. doi: 10.1111/all.15011.
|
[15] |
Buttgereit T, Vera C, Weller K, et al. Lanadelumab efficacy, safety, and injection interval extension in HAE: a real⁃life study[J]. J Allergy Clin Immunol Pract, 2021,9(10):3744⁃3751. doi: 10.1016/j.jaip.2021.04.072.
|
[16] |
Fain O, Du⁃Thanh A, Gobert D, et al. Long⁃term prophylaxis with lanadelumab for HAE: authorization for temporary use in France[J]. Allergy Asthma Clin Immunol, 2022,18(1):30. doi: 10.1186/s13223⁃022⁃00664⁃4.
|
[17] |
Valerieva A, Longhurst HJ. Treatment of hereditary angioedema⁃single or multiple pathways to the rescue[J]. Front Allergy, 2022,3:952233. doi: 10.3389/falgy.2022.952233.
|
[18] |
Cicardi M, Zuraw BL. Angioedema due to bradykinin dysregulation[J]. J Allergy Clin Immunol Pract, 2018,6(4):1132⁃1141. doi: 10.1016/j.jaip.2018.04.022.
|
[19] |
Hwang G, Johri A, Ng S, et al. A review of kallikrein inhibitor lanadelumab in hereditary angioedema[J]. Immunotherapy, 2019,11(11):937⁃944. doi: 10.2217/imt⁃2018⁃0197.
|
[20] |
Syed YY. Lanadelumab: a review in hereditary angioedema[J]. Drugs, 2019,79(16):1777⁃1784. doi: 10.1007/s40265⁃019⁃01206⁃w.
|
[21] |
Riedl MA, Maurer M, Bernstein JA, et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks[J]. Allergy, 2020,75(11):2879⁃2887. doi: 10.1111/all.14416.
|
[22] |
Hahn J, Trainotti S, Wigand MC, et al. Prospective analysis in patients with HAE under prophylaxis with lanadelumab: a real⁃life experience[J]. J Drugs Dermatol, 2020,19(10):978⁃983. doi: 10.36849/JDD.2020.5269.
|
[23] |
Hellu TS, Weiss SL, Smith DM. Successful use of lanadelumab in an elderly patient with type II hereditary angioedema[J]. Fed Pract, 2022,39(9):390⁃392. doi: 10.12788/fp.0315.
|
[24] |
Maurer M, Lumry WR, Li HH, et al. Lanadelumab in patients 2 to less than 12 years old with hereditary angioedema: results from the phase 3 SPRING study[J]. J Allergy Clin Immunol Pract, 2024,12(1):201⁃211.e6. doi: 10.1016/j.jaip.2023.09.009.
|
[25] |
Dorr AD, Chopra C, Coulter TI, et al. Lanadelumab for the prevention of hereditary angioedema attacks: a real⁃world UK audit[J]. Allergy, 2023,78(5):1369⁃1371. doi: 10.1111/all.15620.
|
[26] |
Mendivil J, Malmenäs M, Haeussler K, et al. Indirect comparison of lanadelumab and intravenous C1⁃INH using data from the HELP and CHANGE studies: bayesian and frequentist analyses[J]. Drugs R D, 2021,21(1):113⁃121. doi: 10.1007/s40268⁃021⁃00337⁃4.
|
[27] |
Castaldo AJ, Jervelund C, Corcoran D, et al. Assessing the cost and quality⁃of⁃life impact of on⁃demand⁃only medications for adults with hereditary angioedema. in Allergy and Asthma Proceedings[J]. Allergy Asthma Proc, 2021,42(2):108⁃117. doi: 10.2500/aap.2021.42.200127.
|